DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination

BACKGROUND: Advanced and unresectable bone and soft tissue sarcomas (BSTS) still represent an unmet medical need. We demonstrated that the alkylating agent trabectedin and the PARP1-inhibitor olaparib display antitumor activity in BSTS preclinical models. Moreover, in a phase Ib clinical trial (NCT0...

Descripción completa

Detalles Bibliográficos
Autores principales: Merlini, Alessandra, Centomo, Maria Laura, Ferrero, Giulio, Chiabotto, Giulia, Miglio, Umberto, Berrino, Enrico, Giordano, Giorgia, Brusco, Silvia, Pisacane, Alberto, Maldi, Elena, Sarotto, Ivana, Capozzi, Federica, Lano, Cristina, Isella, Claudio, Crisafulli, Giovanni, Aglietta, Massimo, Dei Tos, Angelo Paolo, Sbaraglia, Marta, Sangiolo, Dario, D’Ambrosio, Lorenzo, Bardelli, Alberto, Pignochino, Ymera, Grignani, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469659/
https://www.ncbi.nlm.nih.gov/pubmed/36110934
http://dx.doi.org/10.3389/fonc.2022.844250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469659/
https://www.ncbi.nlm.nih.gov/pubmed/36110934
http://dx.doi.org/10.3389/fonc.2022.844250

Ejemplares similares